P E Sax

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Strategies for management and treatment of dyslipidemia in HIV/AIDS
    P E Sax
    Division of Infection, Diseases and HIV Program, Brigham and Women s Hospital, Boston, MA 02115, USA
    AIDS Care 18:149-57. 2006
  2. ncbi Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
    Paul E Sax
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Lancet 379:2439-48. 2012
  3. ncbi Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy
    Paul E Sax
    Division of Infectious Diseases and the Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 361:2230-40. 2009
  4. ncbi Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis
    Paul E Sax
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Infect Dis 41:1316-23. 2005
  5. ncbi Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease
    Paul E Sax
    Division of Infectious Disease and the Partners AIDS Research Center, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Acquir Immune Defic Syndr 39:69-77. 2005
  6. ncbi Tolerability and safety of HIV protease inhibitors in adults
    Paul E Sax
    Brigham and Women s Hospital, Division of Infectious Disease, Boston, MA 02115, USA
    J Acquir Immune Defic Syndr 37:1111-24. 2004
  7. ncbi Antiretroviral therapy for treatment-naïve patients: a review of recent literature and the updated guidelines
    Jennifer A Johnson
    Division of Infectious Disease, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Curr Infect Dis Rep 11:311-8. 2009
  8. ncbi Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164
    Paul E Sax
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    HIV Clin Trials 11:248-59. 2010
  9. ncbi Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia
    Paul E Sax
    Division of Infectious Diseases, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 53:197-202. 2011
  10. ncbi Opportunistic infections in HIV disease: down but not out
    P E Sax
    Division of Infectious Diseases, HIV Program, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Infect Dis Clin North Am 15:433-55. 2001

Detail Information

Publications80

  1. ncbi Strategies for management and treatment of dyslipidemia in HIV/AIDS
    P E Sax
    Division of Infection, Diseases and HIV Program, Brigham and Women s Hospital, Boston, MA 02115, USA
    AIDS Care 18:149-57. 2006
    ..Each approach is associated with advantages and limitations and the need to maintain viral suppression must be balanced with the need to treat abnormal lipid levels...
  2. ncbi Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
    Paul E Sax
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Lancet 379:2439-48. 2012
    ..We compared the efficacy and safety of EVG/COBI/FTC/TDF with standard of care-co-formulated efavirenz (EFV)/FTC/TDF-as initial treatment for HIV infection...
  3. ncbi Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy
    Paul E Sax
    Division of Infectious Diseases and the Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 361:2230-40. 2009
    ....
  4. ncbi Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis
    Paul E Sax
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, MA 02115, USA
    Clin Infect Dis 41:1316-23. 2005
    ..Our objective was to determine the clinical impact and cost-effectiveness of genotype resistance testing for treatment-naive patients with chronic HIV infection...
  5. ncbi Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease
    Paul E Sax
    Division of Infectious Disease and the Partners AIDS Research Center, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Acquir Immune Defic Syndr 39:69-77. 2005
    ..Because of the high cost of ENF compared with other antiretroviral agents, our objectives were to determine the potential long-term clinical impact and cost-effectiveness of ENF in these patients...
  6. ncbi Tolerability and safety of HIV protease inhibitors in adults
    Paul E Sax
    Brigham and Women s Hospital, Division of Infectious Disease, Boston, MA 02115, USA
    J Acquir Immune Defic Syndr 37:1111-24. 2004
    ....
  7. ncbi Antiretroviral therapy for treatment-naïve patients: a review of recent literature and the updated guidelines
    Jennifer A Johnson
    Division of Infectious Disease, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Curr Infect Dis Rep 11:311-8. 2009
    ....
  8. ncbi Early antiretroviral therapy for patients with acute aids-related opportunistic infections: a cost-effectiveness analysis of ACTG A5164
    Paul E Sax
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    HIV Clin Trials 11:248-59. 2010
    ..We project the life expectancies, costs, and incremental cost-effectiveness ratios (ICERs) of these strategies...
  9. ncbi Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia
    Paul E Sax
    Division of Infectious Diseases, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 53:197-202. 2011
    ..See the editorial commentary by Morris and Masur, on pages 203-204.)..
  10. ncbi Opportunistic infections in HIV disease: down but not out
    P E Sax
    Division of Infectious Diseases, HIV Program, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Infect Dis Clin North Am 15:433-55. 2001
    ....
  11. ncbi Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results
    Paul E Sax
    Division of Infectious Diseases, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Infect Dis 204:1191-201. 2011
    ..Due to higher virologic failure with ABC/3TC in the high HIV RNA stratum, blinded treatment was stopped in this group, but study follow-up continued for all patients...
  12. ncbi Beyond efficacy: the impact of combination antiretroviral therapy on quality of life
    Paul E Sax
    Brigham and Women s Hospital, Division of Infectious Diseases, 75 Francis Street, PBB A 4, Boston, Massachusetts 02115, USA
    AIDS Patient Care STDS 19:563-76. 2005
    ..As long as the virologic activity of these newer PIs is comparable to that of existing options, differentiating features beyond efficacy are important in the choice of an appropriate treatment regimen for patients with HIV...
  13. ncbi Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection
    Cecile L Tremblay
    Massachusetts General Hospital and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
    AIDS 17:1086-9. 2003
    ..Resistance should be monitored in supervised treatment interruptions trials, because mutations may first be detected only after therapy is interrupted...
  14. ncbi Effectiveness of antiretroviral therapy after protease inhibitor failure: an analytic overview
    Elena Losina
    Department of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USA
    Clin Infect Dis 38:1613-22. 2004
    ..The best response was seen in NNRTI-naive patients receiving NNRTI- and boosted PI-containing regimens. New approaches are needed to achieve better suppression in pretreated HIV-infected patients...
  15. ncbi Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults
    Bruce R Schackman
    Department of Health Policy and Management, Harvard School of Public Health, Boston, MA, USA
    Arch Intern Med 162:2478-86. 2002
    ....
  16. ncbi The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort
    B P Linas
    Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA 02114, USA
    J Viral Hepat 18:506-12. 2011
    ..5), 1.7 (95% CI: 1.4-2.1), and 1.6 (95% CI: 1.3-1.9) respectively. Programs serving HIV/HCV co-infected patients can expect approximately 70% higher rates of utilization than expected from a similar cohort of HIV mono-infected patients...
  17. ncbi Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA
    H E Hsu
    Harvard Medical School, Boston, MA, USA
    HIV Med 12:97-108. 2011
    ..The aim of the study was to quantify the benefits (life expectancy gains) and risks (efavirenz-related teratogenicity) associated with using efavirenz in HIV-infected women of childbearing age in the USA...
  18. ncbi Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection
    M Altfeld
    Partners AIDS Research Center and Infectious Disease Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02129, USA
    J Exp Med 193:169-80. 2001
    ..These data also provide rationale for therapeutic immunization aimed at broadening CTL responses in treated primary HIV infection...
  19. ncbi Central nervous system aspergillosis in patients with human immunodeficiency virus infection. Report of 6 cases and review
    E Mylonakis
    Infectious Disease Division, Massachusetts General Hospital, Boston 02114 2696, USA
    Medicine (Baltimore) 79:269-80. 2000
    ....
  20. ncbi Access to medications and medical care after participation in HIV clinical trials: a systematic review of trial protocols and informed consent documents
    Andrea L Ciaranello
    Division of Infectious Disease, Massachusetts General Hospital, Boston, MA 02114, USA
    HIV Clin Trials 10:13-24. 2009
    ..We describe the frequency with which these posttrial services are described in the protocols and informed consent forms (ICFs) of antiretroviral drug (ARV) trials...
  21. ncbi Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection
    Sigall Kassutto
    Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 42:1024-31. 2006
    ..Protease inhibitor-based and nonnucleoside reverse-transcriptase inhibitor-based regimens show comparable performance in tolerability, time to virological suppression, and CD4+ cell count when used as a first regimen...
  22. ncbi Retroviral rebound syndrome with fatal outcome after discontinuation of antiretroviral therapy
    Amy B Garlin
    Division of Infectious Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 41:e83-5. 2005
    ..Cases of retroviral rebound syndrome reported in the literature are briefly reviewed...
  23. ncbi Predicting virologic failure in an HIV clinic
    Gregory K Robbins
    Harvard Medical School, Boston, Massachusetts, USA
    Clin Infect Dis 50:779-86. 2010
    ..We sought to use data captured in the electronic health record (EHR) to develop and validate a prediction rule for virologic failure among patients being treated for infection with human immunodeficiency virus (HIV)...
  24. ncbi Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy
    Rochelle P Walensky
    Division of Infectious Disease and the Partners AIDS Research Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    J Acquir Immune Defic Syndr 31:27-37. 2002
    ..These results can assist decision makers and those planning clinical trials in defining evidence-based performance measures for primary HIV infection treatment and future trials...
  25. ncbi Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies
    Rajesh T Gandhi
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Infect Dis 191:1435-41. 2005
    ..Development of an anamnestic response after vaccination would suggest previous hepatitis B virus (HBV) infection, in which case vaccination is not necessary...
  26. ncbi Routine human immunodeficiency virus testing: an economic evaluation of current guidelines
    Rochelle P Walensky
    Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, and the Partners AIDS Research Center, Harvard Medical School, Boston, Massachusetts 02114, USA
    Am J Med 118:292-300. 2005
    ..Our objective was to evaluate the clinical effect and cost-effectiveness of current guidelines and of alternate HIV prevalence thresholds...
  27. ncbi The survival benefits of AIDS treatment in the United States
    Rochelle P Walensky
    Division of Infectious Disease and General Medicine, Massachusetts General Hospital, Boston 02114, USA
    J Infect Dis 194:11-9. 2006
    ..As widespread adoption of potent combination antiretroviral therapy (ART) reaches its tenth year, our objective was to quantify the cumulative survival benefits of acquired immunodeficiency syndrome (AIDS) care in the United States...
  28. ncbi Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection
    Sue J Goldie
    Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115 5924, USA
    Am J Med 115:632-41. 2003
    ..To explore the cost-effectiveness of interventions to improve adherence to combination antiretroviral therapy in patients with human immunodeficiency virus (HIV) infection...
  29. ncbi Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial
    Colleen Hadigan
    Massachusetts General Hospital and Brigham and Women s Hospital, Boston, Massachusetts 02114, USA
    Ann Intern Med 140:786-94. 2004
    ....
  30. ncbi Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals
    Rajesh T Gandhi
    Infectious Diseases Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Infect Dis 36:1602-5. 2003
    ..A screening strategy that tests only for HBsAg and anti-HBs in HIV-1-infected patients will miss a large number of individuals with isolated anti-HBc...
  31. ncbi Predictive value of polymerase chain reaction of cerebrospinal fluid for detection of Epstein-Barr virus to establish the diagnosis of HIV-related primary central nervous system lymphoma
    Louise C Ivers
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Clin Infect Dis 38:1629-32. 2004
    ..Of 7 patients with CSF PCR positive for EBV, 2 had PCNSL, and 5 received alternative diagnoses (specificity, 79.1%)...
  32. ncbi Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection
    Eric S Rosenberg
    Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 5:e10555. 2010
    ..clinicaltrials.gov NCT00125099)..
  33. ncbi Therapeutic options for treatment experienced patients: a focus on resistance testing and optimizing background therapy
    Paul E Sax
    Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
    AIDS Read 16:265-75, 277-8. 2006
    ..The development of new agents will be necessary to create highly effective regimens for patients with complicated resistance patterns...
  34. ncbi Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC
    Rochelle P Walensky
    Division of Infectious Disease, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Infect Dis 51:392-400. 2010
    ..We forecast outcomes of this approach if implemented in Washington DC...
  35. ncbi Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution
    Colleen Hadigan
    Program in Nutritional Metabolism, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, USA
    Clin Infect Dis 36:909-16. 2003
    ..Therefore, although CHD risk is increased in HIV-infected patients with fat redistribution, the pattern of fat distribution and sex are potential important components in determining the risk in this population...
  36. ncbi Positive Epstein-Barr virus heterophile antibody tests in patients with primary human immunodeficiency virus infection
    J A Vidrih
    Department of Medicine, Section of General Internal Medicine and Clinical AIDS Program, Boston Medical Center, Boston University School of Medicine, Boston, Massachusetts, USA
    Am J Med 111:192-4. 2001
    ..Patients presenting with nonspecific viral syndromes should be assessed for HIV risk behaviors and tested for primary HIV infection when appropriate...
  37. ncbi Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs: a report of 3 cases
    Holly E Rawizza
    Division of Infectious Diseases, Brigham and Women s Hospital, Boston, Massachusetts, USA
    AIDS Read 18:466-72, 478-9. 2008
    ..Understanding these pharmacokinetic changes might allow clinicians to predict which patients may be more vulnerable to adverse effects or inadequate antiviral activity caused by this drug interaction...
  38. ncbi Male sexual dysfunction associated with antiretroviral therapy
    Amy E Colson
    Channing Laboratory, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    J Acquir Immune Defic Syndr 30:27-32. 2002
    ..69; 95% CI, 0.84-3.37; p =.14), nelfinavir (HR, 1.53; 95% CI, 0.66-3.54; p =.32) and saquinavir (HR, 1.25; 95% CI, 0.53-2.96; p =.60). We conclude that PIs, especially ritonavir, appear to increase the risk of sexual dysfunction...
  39. ncbi The major genetic determinants of HIV-1 control affect HLA class I peptide presentation
    Florencia Pereyra
    Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology MIT and Harvard, Boston, MA, USA
    Science 330:1551-7. 2010
    ..These results implicate the nature of the HLA-viral peptide interaction as the major factor modulating durable control of HIV infection...
  40. ncbi HSV-1 encephalitis complicated by cerebral hemorrhage in an HIV-positive person
    Jonathan Z Li
    Division of Infectious Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    AIDS Read 19:153-5. 2009
    ..He ultimately improved after surgical decompression, treatment with acyclovir, and a switch from a protease inhibitor-based antiretroviral regimen to one including an integrase inhibitor...
  41. ncbi Top stories of 2007
    Paul E Sax
    AIDS Clin Care 20:1-3. 2008
  42. ncbi Report from the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
    Paul E Sax
    AIDS Clin Care 19:99-100. 2007
  43. ncbi Updated DHHS treatment guidelines
    Paul E Sax
    AIDS Clin Care 18:105. 2006
  44. ncbi Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial
    Bruce R Schackman
    Department of Public Health, Weill Cornell Medical College, New York, NY 10021, USA
    Clin Infect Dis 45:1062-70. 2007
    ..We projected the long-term outcomes of this treatment simplification strategy to inform the design of a proposed multicenter, randomized clinical trial...
  45. ncbi FDA approval: etravirine
    Paul E Sax
    AIDS Clin Care 20:17-8. 2008
  46. ncbi Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy
    Judith S Currier
    Circulation 118:e29-35. 2008
  47. ncbi Lower dose of ritonavir approved for use with fosamprenavir
    Paul E Sax
    AIDS Clin Care 19:106. 2007
  48. ncbi XVI International AIDS Conference: Part 1
    Brian A Boyle
    Department of International Medicine and Infectious Diseases, New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, USA
    AIDS Read 16:517-21. 2006
  49. ncbi Report from the 14th Retrovirus Conference. Treatment options for antiretroviral-naive patients
    Paul E Sax
    AIDS Clin Care 19:38-9. 2007
  50. ncbi Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients
    Constance A Benson
    Department of Medicine, University of Colorado Health Sciences Center, 4200 E 9th Avenue, B 168, Denver, CO 80262, USA
    J Infect Dis 185:599-607. 2002
    ..Mean CD4 cell counts increased by 125 cells/muL. Three patients discontinued therapy for drug-related adverse events...
  51. ncbi Report from the XVI International AIDS Conference. Preexposure prophylaxis studies move forward
    Paul E Sax
    AIDS Clin Care 18:101-2. 2006
  52. ncbi XVI International AIDS Conference: Part 2
    Brian A Boyle
    Department of International Medicine and Infectious Diseases, New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, USA
    AIDS Read 16:581-4, 591-2. 2006
  53. ncbi Low prevalence of ongoing hepatitis B viremia in HIV-positive individuals with isolated antibody to hepatitis B core antigen
    Rajesh T Gandhi
    J Acquir Immune Defic Syndr 34:439-41. 2003
  54. ncbi Report from the 11th conference on retroviruses and opportunistic infections. New drugs
    Paul E Sax
    AIDS Clin Care 16:29. 2004
  55. ncbi Report from the 12th Retrovirus Conference. Resistance
    Paul E Sax
    AIDS Clin Care 17:36-7. 2005
  56. ncbi Meeting notes from ICAAC. Tenofovir + ddI: a combination to avoid
    Paul E Sax
    AIDS Clin Care 17:6-7. 2005
  57. ncbi Report from the Tenth Retrovirus Conference. New drugs
    Paul E Sax
    AIDS Clin Care 15:32-3. 2003
  58. ncbi Report from the 12th Retrovirus Conference. New drugs
    Paul E Sax
    AIDS Clin Care 17:37. 2005
  59. ncbi Treating morphologic and metabolic complications in HIV-infected patients on antiretroviral therapy. A consensus statement of an advisory committee of the International Association of Physicians in AIDS Care
    Carl J Fichtenbaum
    IAPAC Mon 11:38-46. 2005
    ..Scientific and clinical research, and other data in published literature and abstracts from scientific conferences were considered by strength of evidence. This document represents the consensus agreement of the Advisory Committee...
  60. ncbi FDA approval: tipranavir
    Paul E Sax
    AIDS Clin Care 17:78. 2005
  61. ncbi Report from the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
    Paul E Sax
    AIDS Clin Care 18:25-6. 2006
  62. ncbi Report from the 13th retrovirus conference. Should we be starting treatment earlier?
    Paul E Sax
    AIDS Clin Care 18:36. 2006
  63. ncbi The lifetime cost of current human immunodeficiency virus care in the United States
    Bruce R Schackman
    Department of Public Health, Weill Medical College of Cornell University, New York, New York 10021, USA
    Med Care 44:990-7. 2006
    ..We sought to project the lifetime cost of medical care for human immunodefiency virus (HIV)-infected adults using current antiretroviral therapy (ART) standards...
  64. ncbi Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients
    Barbara H McGovern
    HIV HCV Co infection Clinic, Lemuel Shattuck Hospital, Jamaica Plain, Jamaica Plain, MA 02494, USA
    Clin Infect Dis 43:365-72. 2006
    ....
  65. ncbi Renal safety of tenofovir disoproxil fumarate
    Paul E Sax
    AIDS Read 17:90-2, 99-104, C3. 2007
    ..We present a review of the renal safety of tenofovir and provide a brief summary of the clinical implications of these data...
  66. ncbi Revised package insert for atazanavir
    Paul E Sax
    AIDS Clin Care 20:23. 2008
  67. ncbi Meeting notes from ICAAC. D-D4FC (Reverset): further data on treatment-experienced patients
    Paul E Sax
    AIDS Clin Care 17:8. 2005
  68. ncbi FDA approval: darunavir
    Paul E Sax
    AIDS Clin Care 18:71. 2006
  69. ncbi Top stories of 2004. Back to the future: lopinavir/ritonavir as "monotherapy"
    Paul E Sax
    AIDS Clin Care 17:4. 2005
  70. ncbi Meeting report. Report from ICAAC
    Paul E Sax
    AIDS Clin Care 18:111-2. 2006
  71. ncbi Meeting report from the XV International AIDS Conference. New drugs
    Paul E Sax
    AIDS Clin Care 16:71-2. 2004
  72. ncbi Meeting notes from ICAAC. NRTI-only regimens: making a comeback?
    Paul E Sax
    AIDS Clin Care 17:8-9. 2005
  73. ncbi One pill, once daily: now an option for HIV patients
    Paul E Sax
    AIDS Clin Care 18:77. 2006
  74. ncbi Meeting report from the XV International AIDS Conference. Structured treatment interruption and other novel treatment strategies
    Paul E Sax
    AIDS Clin Care 16:72-3. 2004
  75. ncbi FDA approval: maraviroc
    Paul E Sax
    AIDS Clin Care 19:75. 2007
  76. ncbi Report from the Tenth Retrovirus Conference. Comparing efavirenz and nevirapine: the 2NN study
    Paul E Sax
    AIDS Clin Care 15:32. 2003
  77. ncbi Report on the XIV International AIDS Conference
    Salim S Abdool Karim
    AIDS Clin Care 14:77-85. 2002
  78. ncbi Meeting notes from the 3rd IAS Conference. Advances in the treatment of hepatitis/HIV coinfection
    Paul E Sax
    AIDS Clin Care 17:97-8. 2005
    ..New studies address the optimal duration of HCV treatment, early predictors of treatment response, and risk factors for liver-related mortality...
  79. ncbi Report from the 13th retrovirus conference. Vicriviroc less effective than efavirenz in treatment-naive patients
    Paul E Sax
    AIDS Clin Care 18:34-5. 2006
  80. ncbi Roundtable. Who should be providing HIV care?
    Jonathan S Appelbaum
    AIDS Clin Care 18:21-4. 2006